ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Merck and Sanofi side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×Merck×Sanofi×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaMerckSanofi
studies on the registry4,1972,4552,425
open to participants now298146104
phase 3 studies under way20011261
reach primary completion within a year1685964
programswith a study of their own in two years119+5 named only8480+12 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaMerckSanofi
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
28%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
23%

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 68 in all. A program counts in each condition its studies name most.

ConditionAstraZenecaMerckSanofi
Carcinoma, Non-Small-Cell Lungall three · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Asthmaall three · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Merck in Asthma: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Asthma in search

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

Influenza, Humanall three · compare here

AstraZeneca in Influenza, Human: 2 programs

  1. AZD4117phase 2
  2. AZD5315phase 2

Their studies: AstraZeneca’s studies of Influenza, Human in search

Merck in Influenza, Human: 1 program

  1. efitazanamivir alfaphase 3

Their studies: Merck’s studies of Influenza, Human in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Merck in Pulmonary Disease, Chronic Obstructive: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Pulmonary Disease, Chronic Obstructive in search

Sanofi in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Pulmonary Disease, Chronic Obstructive in search

Respiratory Syncytial Virus Infectionsall three · compare here

AstraZeneca in Respiratory Syncytial Virus Infections: 1 program

  1. Palivizumabapproved, new study

Their studies: AstraZeneca’s studies of Respiratory Syncytial Virus Infections in search

Merck in Respiratory Syncytial Virus Infections: 1 program

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Respiratory Syncytial Virus Infections in search

Sanofi in Respiratory Syncytial Virus Infections: 9 programs

  1. RSVt Vaccinephase 3
  2. RSV+HMPV vaccinephase 2
  3. RSV vaccine formulation 1 dosephase 2
  4. H5 Flu IMP 2phase 1
  5. Inosine Monophosphatephase 1

and 4 more — sign in to see them all

Their studies: Sanofi’s studies of Respiratory Syncytial Virus Infections in search

Diabetes Mellitus, Type 2all three · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Merck in Diabetes Mellitus, Type 2: 4 programs

  1. efinopegdutidephase 2
  2. MK-1403phase 1
  3. MK-2828phase 1
  4. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Stomach Neoplasmsall three · compare here

Merck in Stomach Neoplasms: 1 program

  1. pembrolizumabapproved, new study

Their studies: Merck’s studies of Stomach Neoplasms in search

Sanofi in Stomach Neoplasms: 1 program

  1. Daxokafusp Alfaphase 2

Their studies: Sanofi’s studies of Stomach Neoplasms in search

Carcinoma, Renal Cellall three · compare here

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

Merck in Carcinoma, Renal Cell: 4 programs

  1. belzutifanphase 3
  2. intismeran autogenephase 3
  3. raludotatug deruxtecanphase 3
  4. zanzalintinibphase 3

Their studies: Merck’s studies of Carcinoma, Renal Cell in search

Sanofi in Carcinoma, Renal Cell: 1 program

  1. Biological Productsphase 1

Their studies: Sanofi’s studies of Carcinoma, Renal Cell in search

Colitis, Ulcerativeall three · compare here

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

Merck in Colitis, Ulcerative: 3 programs

  1. tulisokibartphase 3
  2. MK-8690phase 2
  3. MK-6194phase 2

Their studies: Merck’s studies of Colitis, Ulcerative in search

Sanofi in Colitis, Ulcerative: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Colitis, Ulcerative in search

Dermatitis, Atopicall three · compare here

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Merck in Dermatitis, Atopic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Dermatitis, Atopic in search

Sanofi in Dermatitis, Atopic: 5 programs

  1. lunsekimigphase 3
  2. amlitelimabphase 3
  3. itepekimabphase 3
  4. Dupilumab coformulated with berahyaluronidase alfaphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Dermatitis, Atopic in search

COVID-19all three · compare here

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

Merck in COVID-19: 2 programs

  1. molnupiravirphase 3
  2. frespaciguatphase 3

Their studies: Merck’s studies of COVID-19 in search

Sanofi in COVID-19: 3 programs

  1. NVX-COV2705phase 3
  2. Biological Productsphase 1
  3. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study

Their studies: Sanofi’s studies of COVID-19 in search

Hypercholesterolemiaall three · compare here

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Merck in Hypercholesterolemia: 3 programs

  1. enlicitide decanoatephase 3
  2. enlicitide chloridephase 3
  3. rosuvastatinphase 3

Their studies: Merck’s studies of Hypercholesterolemia in search

Sanofi in Hypercholesterolemia: 1 program

  1. Cholestyramine Resinphase 3

Their studies: Sanofi’s studies of Hypercholesterolemia in search

Lupus Erythematosus, Systemicall three · compare here

Merck in Lupus Erythematosus, Systemic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Lupus Erythematosus, Systemic in search

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

Multiple Myelomaall three · compare here

Merck in Multiple Myeloma: 1 program

  1. sotaterceptapproved, new study

Their studies: Merck’s studies of Multiple Myeloma in search

Sanofi in Multiple Myeloma: 1 program

  1. Anti-GPRC5D Monoclonal Antibody SAR446523phase 1

Their studies: Sanofi’s studies of Multiple Myeloma in search

Arthritis, Rheumatoidall three · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Merck in Arthritis, Rheumatoid: 1 program

  1. MK-8690phase 2

Their studies: Merck’s studies of Arthritis, Rheumatoid in search

Sanofi in Arthritis, Rheumatoid: 2 programs

  1. balinatunfibphase 2
  2. sarilumabapproved, new study

Their studies: Sanofi’s studies of Arthritis, Rheumatoid in search

Crohn Diseaseall three · compare here

AstraZeneca in Crohn Disease: 1 program

  1. AZD7798phase 2

Their studies: AstraZeneca’s studies of Crohn Disease in search

Merck in Crohn Disease: 1 program

  1. tulisokibartphase 3

Their studies: Merck’s studies of Crohn Disease in search

Sanofi in Crohn Disease: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Crohn Disease in search

Colorectal Neoplasmsall three · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Merck in Colorectal Neoplasms: 2 programs

  1. zanzalintinibphase 3
  2. Cetuximabphase 3

Their studies: Merck’s studies of Colorectal Neoplasms in search

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Neoplasms2 of 3 · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

–
Renal Insufficiency2 of 3 · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Merck in Renal Insufficiency: 7 programs

  1. calderasibphase 3
  2. nemtabrutinibphase 3
  3. alimatravirphase 3
  4. enlicitide chloridephase 3
  5. doravirinephase 3

and 2 more — sign in to see them all

Their studies: Merck’s studies of Renal Insufficiency in search

–
Prostatic Neoplasms2 of 3 · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Merck in Prostatic Neoplasms: 1 program

  1. opevesostatphase 3

Their studies: Merck’s studies of Prostatic Neoplasms in search

–
Breast Neoplasms2 of 3 · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

–
Leukemia, Lymphocytic, Chronic, B-Cell2 of 3 · compare here

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Merck in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3
  2. nemtabrutinibphase 3
  3. zilovertamab vedotinphase 3

Their studies: Merck’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

–
Obesity2 of 3 · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Merck in Obesity: 3 programs

  1. efinopegdutidephase 2
  2. TERN-601phase 2
  3. Metforminapproved, new study

Their studies: Merck’s studies of Obesity in search

–
Triple Negative Breast Neoplasms2 of 3 · compare here

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Merck in Triple Negative Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. zilovertamab vedotinphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Triple Negative Breast Neoplasms in search

–
Kidney Failure, Chronic2 of 3 · compare here

AstraZeneca in Kidney Failure, Chronic: 1 program

  1. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Kidney Failure, Chronic in search

Merck in Kidney Failure, Chronic: 5 programs

  1. opevesostatphase 3
  2. efinopegdutidephase 2
  3. MK-2060phase 2
  4. MK-2828phase 1
  5. bictegravirphase 1

Their studies: Merck’s studies of Kidney Failure, Chronic in search

–
Lymphoma, Follicular2 of 3 · compare here

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Merck in Lymphoma, Follicular: 1 program

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3

Their studies: Merck’s studies of Lymphoma, Follicular in search

–
Melanoma2 of 3 · compare here

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

Merck in Melanoma: 3 programs

  1. intismeran autogenephase 3
  2. BCG Vaccinephase 2
  3. pembrolizumabapproved, new study

Their studies: Merck’s studies of Melanoma in search

–
Ovarian Neoplasms2 of 3 · compare here

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

–
Diabetes Mellitus, Type 12 of 3 · compare here

AstraZeneca in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 1 in search

–

Sanofi in Diabetes Mellitus, Type 1: 4 programs

  1. frexalimabphase 3
  2. brivekimigphase 2
  3. Biological Productsphase 1
  4. teplizumabapproved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 1 in search

Endometrial Neoplasms2 of 3 · compare here

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

Merck in Endometrial Neoplasms: 1 program

  1. sacituzumab tirumotecanphase 3

Their studies: Merck’s studies of Endometrial Neoplasms in search

–
Hepatic Insufficiency2 of 3 · compare here

AstraZeneca in Hepatic Insufficiency: 2 programs

  1. atirmociclibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Hepatic Insufficiency in search

Merck in Hepatic Insufficiency: 3 programs

  1. bomedemstatphase 3
  2. ulonivirinephase 3
  3. enlicitide chloridephase 3

Their studies: Merck’s studies of Hepatic Insufficiency in search

–
Hyperlipidemias2 of 3 · compare here

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Merck in Hyperlipidemias: 2 programs

  1. enlicitide chloridephase 3
  2. rosuvastatinphase 3

Their studies: Merck’s studies of Hyperlipidemias in search

–
Nasal Polyps2 of 3 · compare here

AstraZeneca in Nasal Polyps: 2 programs

  1. tezepelumabapproved, new study
  2. benralizumabapproved, new study

Their studies: AstraZeneca’s studies of Nasal Polyps in search

–

Sanofi in Nasal Polyps: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Nasal Polyps in search

Small Cell Lung Carcinoma2 of 3 · compare here

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Merck in Small Cell Lung Carcinoma: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. gocatamigphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Small Cell Lung Carcinoma in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Merck in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. Cetuximabphase 3
  2. pembrolizumabapproved, new study

Their studies: Merck’s studies of Squamous Cell Carcinoma of Head and Neck in search

–
Urinary Bladder Neoplasms2 of 3 · compare here

AstraZeneca in Urinary Bladder Neoplasms: 2 programs

  1. datopotamab deruxtecanphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Urinary Bladder Neoplasms in search

Merck in Urinary Bladder Neoplasms: 3 programs

  1. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2
  2. BCG Vaccinephase 2
  3. pembrolizumabapproved, new study

Their studies: Merck’s studies of Urinary Bladder Neoplasms in search

–
Alzheimer Disease2 of 3 · compare here–

Merck in Alzheimer Disease: 3 programs

  1. MK-2214phase 2
  2. BCG Vaccinephase 2
  3. MK-1167phase 2

Their studies: Merck’s studies of Alzheimer Disease in search

Sanofi in Alzheimer Disease: 1 program

  1. SAR448851phase 2

Their studies: Sanofi’s studies of Alzheimer Disease in search

Dyslipidemias2 of 3 · compare here

AstraZeneca in Dyslipidemias: 3 programs

  1. laroprovstatphase 3
  2. AZD4954phase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Dyslipidemias in search

Merck in Dyslipidemias: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Dyslipidemias in search

–
Lung Neoplasms2 of 3 · compare here

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Merck in Lung Neoplasms: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. raludotatug deruxtecanphase 3
  3. Rescue Medicationsphase 2

Their studies: Merck’s studies of Lung Neoplasms in search

–
Lymphoma, B-Cell2 of 3 · compare here–

Sanofi in Lymphoma, B-Cell: 1 program

  1. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lymphoma, B-Cell in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

–
Neoplasm Metastasis2 of 3 · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Merck in Neoplasm Metastasis: 1 program

  1. MK-8294phase 1

Their studies: Merck’s studies of Neoplasm Metastasis in search

–
Psoriasis2 of 3 · compare here–

Merck in Psoriasis: 1 program

  1. MK-8644phase 1

Their studies: Merck’s studies of Psoriasis in search

Sanofi in Psoriasis: 3 programs

  1. balinatunfibphase 2
  2. belumosudilapproved, new study
  3. teplizumabapproved, new study

Their studies: Sanofi’s studies of Psoriasis in search

Bronchiectasis2 of 3 · compare here

AstraZeneca in Bronchiectasis: 1 program

  1. AZD0292phase 2

Their studies: AstraZeneca’s studies of Bronchiectasis in search

–

Sanofi in Bronchiectasis: 2 programs

  1. itepekimabphase 3
  2. zetrukibartphase 2

Their studies: Sanofi’s studies of Bronchiectasis in search

Burkitt Lymphoma2 of 3 · compare here–
Colonic Neoplasms2 of 3 · compare here

AstraZeneca in Colonic Neoplasms: 2 programs

  1. oleclumabphase 3
  2. monalizumabphase 3

Their studies: AstraZeneca’s studies of Colonic Neoplasms in search

Merck in Colonic Neoplasms: 1 program

  1. calderasibphase 3

Their studies: Merck’s studies of Colonic Neoplasms in search

–
Hypertension2 of 3 · compare here

AstraZeneca in Hypertension: 2 programs

  1. baxdrostatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypertension in search

Merck in Hypertension: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Hypertension in search

–
Hypertension, Pulmonary2 of 3 · compare here–

Merck in Hypertension, Pulmonary: 2 programs

  1. frespaciguatphase 3
  2. sotaterceptapproved, new study

Their studies: Merck’s studies of Hypertension, Pulmonary in search

Sanofi in Hypertension, Pulmonary: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Hypertension, Pulmonary in search

Multiple Sclerosis2 of 3 · compare here–

Sanofi in Multiple Sclerosis: 2 programs

  1. frexalimabphase 3
  2. Cholestyramine Resinphase 3

Their studies: Sanofi’s studies of Multiple Sclerosis in search

Pneumococcal Infections2 of 3 · compare here–

Merck in Pneumococcal Infections: 2 programs

  1. V118Cphase 1
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Pneumococcal Infections in search

Sanofi in Pneumococcal Infections: 1 program

  1. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Pneumococcal Infections in search

Pulmonary Arterial Hypertension2 of 3 · compare here–

Merck in Pulmonary Arterial Hypertension: 2 programs

  1. frespaciguatphase 3
  2. sotaterceptapproved, new study

Their studies: Merck’s studies of Pulmonary Arterial Hypertension in search

Sanofi in Pulmonary Arterial Hypertension: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Pulmonary Arterial Hypertension in search

Purpura, Thrombocytopenic, Idiopathic2 of 3 · compare here

AstraZeneca in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. pirtobrutinibphase 2

Their studies: AstraZeneca’s studies of Purpura, Thrombocytopenic, Idiopathic in search

–

Sanofi in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. rilzabrutinibphase 3
  2. riliprubartphase 3

Their studies: Sanofi’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Anemia, Sickle Cell2 of 3 · compare here

AstraZeneca in Anemia, Sickle Cell: 1 program

  1. tarperprumigphase 2

Their studies: AstraZeneca’s studies of Anemia, Sickle Cell in search

–

Sanofi in Anemia, Sickle Cell: 1 program

  1. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Anemia, Sickle Cell in search

Coronary Artery Disease2 of 3 · compare here

AstraZeneca in Coronary Artery Disease: 1 program

  1. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Coronary Artery Disease in search

Merck in Coronary Artery Disease: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Coronary Artery Disease in search

–
Coronavirus Infections2 of 3 · compare here–

Merck in Coronavirus Infections: 1 program

  1. molnupiravirphase 3

Their studies: Merck’s studies of Coronavirus Infections in search

Sanofi in Coronavirus Infections: 1 program

  1. sarilumabapproved, new study

Their studies: Sanofi’s studies of Coronavirus Infections in search

Diabetes Mellitus2 of 3 · compare here

AstraZeneca in Diabetes Mellitus: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus in search

Merck in Diabetes Mellitus: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus in search

–
Eosinophilic Esophagitis2 of 3 · compare here

AstraZeneca in Eosinophilic Esophagitis: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Eosinophilic Esophagitis in search

–

Sanofi in Eosinophilic Esophagitis: 1 program

  1. dupilumabapproved, new study

Their studies: Sanofi’s studies of Eosinophilic Esophagitis in search

Fallopian Tube Neoplasms2 of 3 · compare here

AstraZeneca in Fallopian Tube Neoplasms: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Fallopian Tube Neoplasms in search

Merck in Fallopian Tube Neoplasms: 1 program

  1. raludotatug deruxtecanphase 3

Their studies: Merck’s studies of Fallopian Tube Neoplasms in search

–
Fasting2 of 3 · compare here

AstraZeneca in Fasting: 1 program

  1. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Fasting in search

Merck in Fasting: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Fasting in search

–
Head and Neck Neoplasms2 of 3 · compare here

AstraZeneca in Head and Neck Neoplasms: 1 program

  1. monalizumabphase 3

Their studies: AstraZeneca’s studies of Head and Neck Neoplasms in search

Merck in Head and Neck Neoplasms: 1 program

  1. Cetuximabphase 3

Their studies: Merck’s studies of Head and Neck Neoplasms in search

–
Hematologic Neoplasms2 of 3 · compare here

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

Merck in Hematologic Neoplasms: 1 program

  1. nemtabrutinibphase 3

Their studies: Merck’s studies of Hematologic Neoplasms in search

–
Liver Diseases2 of 3 · compare here

AstraZeneca in Liver Diseases: 1 program

  1. AZD2389phase 2

Their studies: AstraZeneca’s studies of Liver Diseases in search

–

Sanofi in Liver Diseases: 1 program

  1. venglustatphase 3

Their studies: Sanofi’s studies of Liver Diseases in search

Macular Degeneration2 of 3 · compare here–

Merck in Macular Degeneration: 1 program

  1. remigromigphase 3

Their studies: Merck’s studies of Macular Degeneration in search

Sanofi in Macular Degeneration: 1 program

  1. SAR402663phase 2

Their studies: Sanofi’s studies of Macular Degeneration in search

Malaria2 of 3 · compare here–

Merck in Malaria: 1 program

  1. MK-7602phase 1

Their studies: Merck’s studies of Malaria in search

Sanofi in Malaria: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Malaria in search

Non-alcoholic Fatty Liver Disease2 of 3 · compare here

AstraZeneca in Non-alcoholic Fatty Liver Disease: 1 program

  1. AZD9550phase 2

Their studies: AstraZeneca’s studies of Non-alcoholic Fatty Liver Disease in search

Merck in Non-alcoholic Fatty Liver Disease: 1 program

  1. efinopegdutidephase 2

Their studies: Merck’s studies of Non-alcoholic Fatty Liver Disease in search

–
Pneumonia, Pneumococcal2 of 3 · compare here–

Merck in Pneumonia, Pneumococcal: 1 program

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Pneumonia, Pneumococcal in search

Sanofi in Pneumonia, Pneumococcal: 1 program

  1. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Pneumonia, Pneumococcal in search

Polycystic Kidney, Autosomal Dominant2 of 3 · compare here

AstraZeneca in Polycystic Kidney, Autosomal Dominant: 1 program

  1. AZD1613phase 1

Their studies: AstraZeneca’s studies of Polycystic Kidney, Autosomal Dominant in search

–

Sanofi in Polycystic Kidney, Autosomal Dominant: 1 program

  1. venglustatphase 3

Their studies: Sanofi’s studies of Polycystic Kidney, Autosomal Dominant in search

Uterine Cervical Neoplasms2 of 3 · compare here

AstraZeneca in Uterine Cervical Neoplasms: 1 program

  1. volrustomigphase 3

Their studies: AstraZeneca’s studies of Uterine Cervical Neoplasms in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Merck 40 of 84 · Sanofi 53 of 80 programs (52 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, Sanofi: 12).